Ferring to Highlight Phase 3 Data for Cervical Ripening Candidate at Society for Maternal-Fetal Medicine Annu... ( SAN FRANCISCO Feb. 12 2013 /- S...)

Ferring to Highlight Phase 3 Data for Cervical Ripening Candidate at Society for Maternal-Fetal Medicine Annual Meeting

Date:2/12/2013

SAN FRANCISCO, Feb. 12, 2013 /PRNewswire/ -- Ferring Pharmaceuticals will present pivotal Phase 3 efficacy and safety data from its EXPEDITE* study for its investigational controlled release misoprostol vaginal insert (MVI) at the 33^rd annual meeting of the Society for Maternal-Fetal Medicine (SMFM) in San Francisco, February 11 - 16. These and other research findings formed the basis for Ferring's New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) supporting the use of the controlled release MVI as a treatment option for cervical ripening as part of the labor induction process.

Studies accepted for presentation include

An oral presentation on Sat., Feb. 16 (9 a.m. – 9:15 a.m. PST), titled "Efficacy and safety of misoprostol vaginal insert compared with dinoprostone vaginal insert for labor induction" (lead author: Deborah A. Wing , MD, University of California, Irvine); and
A poster presentation on Thurs., Feb. 14 (3:30 p.m. – 5:30 p.m. PST), titled "Comparison of misoprostol vaginal insert and dinoprostone vaginal insert: incidence of treatment-emergent adverse events" (lead author: Stacey Ehrenberg-Buchner , MD, University of Michigan Health System).

*The EXPEDITE Study: A Phase 3, double blind, randomized, multicenter study of exogenous prostaglandin comparing the efficacy and safety of the misoprostol vaginal insert (MVI) 200 mcg to the dinoprostone vaginal insert for reducing time to vaginal delivery in pregnant women at term.

For further information, contact:
Leila Boukassi
MSL New York
leila.boukassi@mslgroup.com; 646.500.7735

About Ferring Pharmaceuticals:
Ferring Pharmaceuticals is a research-driven speciality b
'/>"/>

SOURCE Ferring Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine technology :

1. ESTEVE Fosters R & D by Transferring its Center for Drug Discovery to the Science Park of Barcelona (PCB)
2. Ferring Pharmaceuticals Inc. Named 10th Fastest Growing New Jersey Company
3. Ferring Pharmaceuticals Inc. Recognized for Best-in-Class Work-Life Portfolio
4. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
5. Staffing and Performance Benchmarks for Quality Function Highlight New Medical Device Study
6. Isis Reports Financial Results and Highlights for First Quarter 2012
7. Delcath Highlights First Quarter 2012 And Recent Accomplishments
8. Soligenix Reports First Quarter 2012 Financial Results and Highlights Recent Accomplishments
9. Volcano to Highlight its Leadership in Precision Guided Therapy at EuroPCR 2012
10. "Emergency Medical Services Week" Highlights Stroke Survivors and Awareness
11. PharMEDium Highlights Enhanced Labeling for ICU Services at Critical Care Expo

Post Your Comments:

(Date:1/15/2014)... LAWRENCEVILLE, N.J. , Jan. 15, 2014 Celsion Corporation (the ... it has received commitments from institutional investors to purchase ... common stock in an at-the-market registered direct offering, led ... Company entered into definitive purchase agreements with these investors ...

(Date:1/15/2014)... January 15, 2014 Shire plc (LSE: SHP, NASDAQ: ... of Fair Trading (OFT) approval condition to the announced tender offer ... As a result of the waiver, the transaction ... complete the tender offer on January 24, 2014 following the currently ...

(Date:1/15/2014)... , January 15, 2014 BreedIT Corp ... exclusive worldwide distributor of highly sophisticated agro-breeding solutions for ... 7, 2014, the Company,s board of directors appointed chemistry ... as its new member of the board. ...

Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2 Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3 Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2 Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3 BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2 BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3

[0] Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering [0] Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc.[0] BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors

... Data Provides Ophthalmologists Critical Insight on Novel Beta ... Radiation Epiretinal Therapy, ... a one-year feasibility study of the company,s novel beta,radiation epiretinal therapy ... Annual Meeting of the American Academy of,Ophthalmology in New Orleans, Louisiana. ...

... American College of Rheumatology Annual Congress -, ... BMY ) today announced the results of three ... showed ORENCIA(R) (abatacept) improved daily,activity participation, such as ... sleep quality in adult rheumatoid arthritis,(RA) patients who ...

NeoVista, Inc. Presents New Data on Its Novel Wet AMD Therapy at AAO Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept)

(Date:7/9/2014)... OH, July 10, 2014 -- The World Health Organization ... minutes of moderate to vigorous physical activity (MVPA) each ... of their MVPA during school hours. Therefore, it ... hours would increase MVPA. In a new study ... , researchers confirmed that time spent outdoors after school ...

(Date:7/9/2014)... TORONTO, July 10, 2014 For the first time, ... urban Aboriginal population in Canada uses health care. A ... database to clearly demonstrate the unique challenges faced by ... at St. Michael,s Hospital. , The findings, published ... between urban First Nations individuals and the general population. ...

(Date:7/9/2014)... the Perelman School of Medicine at the University of ... have received an $8 million grant from the National ... light therapy (PDT) in patients with malignant pleural mesothelioma, ... manifests itself in the lining of the lungs and ... grant will fund a clinical trial and additional studies ...

(Date:7/9/2014)... A network of signals active in almost all types ... into overdrive, and may help fuel a tumour,s uncontrolled ... of Cancer Research, London, identified a molecular trigger responsible ... the cellular factory that makes the building blocks ... in the TOR signalling pathway, called SREBP, controls the ...

(Date:7/9/2014)... Studying the most common type of lung cancer, researchers ... a role in forming tumors. The new knowledge may ... these genetic changes already are available or are in ... , investigators from The Cancer Genome Atlas (TCGA), including ... Louis, Harvard Medical School and other institutions, studied tumors ...

Breaking Medicine News(10 mins):Health News:Go play outside! Outdoor time promotes physical activity in youth 2 Health News:Urban Aboriginal people face unique health challenges 2 Health News:Penn mesothelioma program receives $8 million NCI grant 2 Health News:Signal may send cancer's cellular factories into overdrive 2 Health News:Lung cancer study hints at new treatments 2

[0] Go play outside! Outdoor time promotes physical activity in youth [0] Urban Aboriginal people face unique health challenges [0] Penn mesothelioma program receives $8 million NCI grant [0] Signal may send cancer's cellular factories into overdrive [0] Lung cancer study hints at new treatments

... Reporter , MONDAY, Feb. 28 (HealthDay News) -- The battle of ... players in the fight to reduce waistlines, two new studies report. ... told by their doctors that they are overweight or obese, they ... likely to want to lose weight and to try to lose ...

... State University School of Medicine physician-researcher has developed a ... The treatment is based on a naturally occurring human ... cells into killing themselves. The unique concept, patented ... cells that are resistant to routine treatments such as ...

... Feb. 28, 2011 Los Angeles Biomedical Research ... Inc., a Japanese biotechnology firm, have entered into a ... in regenerative medicine, "Cell Sheet Engineering," LA BioMed President ... "LA BioMed is working to accelerate the pace of ...

... , A new University of Colorado Boulder study indicates ... in helping to treat people with mild traumatic brain ... U.S. war veterans returning home. The study involved ... are used to stimulate particular points on a person,s ...

... (BUSM) have found that patients with node negative T3 ... surgery had more than three times the survival rate ... appear on-line in the Journal of Thoracic and ... total of 110 patients who underwent surgical resection for ...

... brain imaging study at the U.S. Department of Energy,s (DOE) ... subjects and those who compulsively overeat, or binge: In binge ... smell of favorite foods triggers a spike in dopamine - ... - published online on February 24, 2011, in the journal ...

Cached Medicine News:Health News:Doctors Can Influence Patients to Lose Weight: Studies 2 Health News:Doctors Can Influence Patients to Lose Weight: Studies 3 Health News:WSU researcher creates patented personalized therapy that causes cancer cells to kill themselves 2 Health News:WSU researcher creates patented personalized therapy that causes cancer cells to kill themselves 3 Health News:WSU researcher creates patented personalized therapy that causes cancer cells to kill themselves 4 Health News:LA BioMed and CellSeed to launch joint research project on regenerative medicine technology 2 Health News:U. of Colorado study shows acupressure effective in helping to treat traumatic brain injury 2 Health News:U. of Colorado study shows acupressure effective in helping to treat traumatic brain injury 3 Health News:U. of Colorado study shows acupressure effective in helping to treat traumatic brain injury 4 Health News:Binge eaters' dopamine levels spike at sight, smell of food 2 Health News:Binge eaters' dopamine levels spike at sight, smell of food 3

Doctors Can Influence Patients to Lose Weight: Studies WSU researcher creates patented personalized therapy that causes cancer cells to kill themselves LA BioMed and CellSeed to launch joint research project on regenerative medicine technology U. of Colorado study shows acupressure effective in helping to treat traumatic brain injury BUSM study shows chemoradiotherapy prior to surgery improves survival Binge eaters' dopamine levels spike at sight, smell of food

... a single use rapid test, for the detection ... whole blood (venipuncture). Uni-Gold Recombigen HIV is intended ... an aid in diagnosis of infection with HIV-1. ... multi-test algorithms designed for the statistical validation of ...

... HIV-1 Oral Specimen Collection Device is a safe, ... antibodies. Testing with the OraSure HIV-1 Oral Specimen ... has been shown to be more than 99% ... cotton fiber pad attached to a nylon stick ...

The Becton™ Colles Fracture Plate has proven clinical outcomes and has excellent patient acceptance compared to external fixation. It provides a cost effective treatment option through a simple...

... Angle CHS System takes the time proven ... , ,The VHS® Supracondylar Cable Plate is ... distal femur fractures including periprosthetic fractures. The ... variable angle of the barrel and the ...

Medicine Products:

Uni-Gold Recombigen HIV OraSure HIV-1 Oral Specimen Collection Device Becton™ Colles Fracture Plate VHS® Supracondylar Cable Plate